European Low and Intermediate Risk Neuroblastoma Protocol
NCT ID: NCT01728155
Last Updated: 2023-09-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
685 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The European study, LINES 2009 (Low and Intermediate Risk Neuroblastoma European Study), groups together in a single protocol the treatment of all patients with "non high risk" neuroblastoma (NB), with stratification into two groups: low risk and intermediate risk. These two separate cohorts are included in one single protocol to enable patient data from these two groups to be entered into a common database, as the current prognostic classifications determining treatment may evolve further with subsequent more detailed molecular analysis of the tumours.
1\. LOW RISK STUDY
The Low Risk Study is proposed in order to:
* minimise the amount of treatment (chemotherapy and surgery) for all appropriate low risk patients, who in previous studies have been shown to have an excellent long-term outcome (as in the SIOPEN 99.1-2 infant neuroblastoma studies where the overall survival was greater than 97%(H. Rubie, JCO).
* improve the EFS and maintain the OS (overall survival) in L2 and Ms patients with a SCA(Segmental Cromosomal Aberration) genomic profile tumour (presence of any segmental chromosomal change (SCA)) by electively treating these patients with chemotherapy despite the absence of symptoms.
2\) INTERMEDIATE RISK STUDY
The Intermediate Risk Study is proposed in order to:
* reduce the amount of chemotherapy for differentiating histology INRG (International Neuroblastoma Risk Group) stage L2 NB and ganglioneuroblastoma nodular patients who in previous SIOPEN study have been shown to have an excellent long-term outcome;
* increase the amount of treatment (radiotherapy and 13-cis-RA (13-cis-Retinoic Acid) for poorly differentiated or undifferentiated histology INRG stage L2 NB or ganglioneuroblastoma nodular patients in order to improve the EFS registered in the previous SIOPEN study;
* improve the EFS (Event Free Survival) of MYCN (V-Myc myelocytomatosis viral related oncogene, NB derived ,avian )amplified INSS (International NB Staging System) stage 1 NB patients with the introduction of adjuvant treatment;
* maintain the very good results obtained in previous SIOPEN study for INRG stage M infants with a moderate treatment.
NEONATAL SUPRARENAL MASSES
The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation
1\. LOW RISK STUDY
The Low Risk Study is proposed in order to:
* minimise the amount of treatment (chemotherapy and surgery) for all appropriate low risk patients, who in previous studies have been shown to have an excellent long-term outcome (as in the SIOPEN 99.1-2 infant neuroblastoma studies where the overall survival was greater than 97%(H. Rubie, JCO).
* improve the EFS and maintain the OS (overall survival) in L2 and Ms patients with a SCA(Segmental Cromosomal Aberration) genomic profile tumour (presence of any segmental chromosomal change (SCA)) by electively treating these patients with chemotherapy despite the absence of symptoms.
2\) INTERMEDIATE RISK STUDY
The Intermediate Risk Study is proposed in order to:
* reduce the amount of chemotherapy for differentiating histology INRG (International Neuroblastoma Risk Group) stage L2 NB and ganglioneuroblastoma nodular patients who in previous SIOPEN study have been shown to have an excellent long-term outcome;
* increase the amount of treatment (radiotherapy and 13-cis-RA (13-cis-Retinoic Acid) for poorly differentiated or undifferentiated histology INRG stage L2 NB or ganglioneuroblastoma nodular patients in order to improve the EFS registered in the previous SIOPEN study;
* improve the EFS (Event Free Survival) of MYCN (V-Myc myelocytomatosis viral related oncogene, NB derived ,avian )amplified INSS (International NB Staging System) stage 1 NB patients with the introduction of adjuvant treatment;
* maintain the very good results obtained in previous SIOPEN study for INRG stage M infants with a moderate treatment.
NEONATAL SUPRARENAL MASSES
The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
NCT01553149
Neurofibromatosis Type 1
Recurrent Childhood Pilocytic Astrocytoma
Recurrent Childhood Visual Pathway Glioma
COMPLETED
PHASE2
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967
Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
+1 more
ACTIVE_NOT_RECRUITING
PHASE3
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
NCT00276679
Neuroblastoma
COMPLETED
PHASE2
Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only
NCT00416559
Long-term Effects Secondary to Cancer Therapy in Children
Neuroblastoma
UNKNOWN
PHASE2
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
NCT03057626
Recurrent Neuroblastoma
Stage 2A Neuroblastoma
Stage 2B Neuroblastoma
+3 more
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. LOW RISK STUDY
The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations:
* Children aged ≤ 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2).
* Children aged ≤ 12 months with disseminated neuroblastoma without bone, pleura, lung or CNS (Central Nervous System) disease (stage INRG Ms)
2\) INTERMEDIATE RISK STUDY
The intermediate risk group of patients includes NB patients in the following clinical situations:
* Children aged \>18 months with localised neuroblastoma without MYCN amplification, associated with image defined risk factors precluding upfront surgery (stage INRG L2).
* Children aged ≤12 months with disseminated neuroblastoma involving bone, pleura, lung and/or CNS (stage INRG M), without MYCN amplification.
* Children with localised resected NB (stage INSS I) with MYCN amplification. NEONATAL SUPRARENAL MASSES
The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation
The low risk group of patients includes NB patients without MYCN amplification with or without life threatening symptoms in the following clinical situations:
* Children aged ≤ 18 months with localised neuroblastoma associated with image defined risk factors precluding upfront surgery (stage INRG L2).
* Children aged ≤ 12 months with disseminated neuroblastoma without bone, pleura, lung or CNS (Central Nervous System) disease (stage INRG Ms)
2\) INTERMEDIATE RISK STUDY
The intermediate risk group of patients includes NB patients in the following clinical situations:
* Children aged \>18 months with localised neuroblastoma without MYCN amplification, associated with image defined risk factors precluding upfront surgery (stage INRG L2).
* Children aged ≤12 months with disseminated neuroblastoma involving bone, pleura, lung and/or CNS (stage INRG M), without MYCN amplification.
* Children with localised resected NB (stage INSS I) with MYCN amplification. NEONATAL SUPRARENAL MASSES
The incidence of suprarenal tumours/masses has increased in the last decade due to the expanded use of prenatal ultrasonography in routine obstetric care and in the neonatal and early infancy care. The differential diagnosis of these masses ranges from benign (adrenal haemorrhage) to malignant processes (neuroblastoma, adrenal carcinoma). Knowledge on perinatal suprarenal masses, although based on a relatively large literature, is scattered amongst studies on very few cases with no methodical approach and often short follow up. Therefore, the optimal management of these masses has not been clearly defined. Neuroblastoma at this age is an intriguing entity with a very good prognosis in most cases. The SIOPEN Group, based on their results in the first multicenter European Trial for infants with neuroblastoma (INES) and the world-wide experience provided in the literature, is launching this European surveillance study (Multi-centre, non-blinded, one armed prospective trial) for these masses. Treatment: Observation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
initial observation (chemotherapy is only given if there is subsequent progression)
Group Type
NO_INTERVENTION
No interventions assigned to this group
Group 1: chemotherapy
chemotherapy and surgery
Group Type
ACTIVE_COMPARATOR
chemotherapy
Intervention Type
DRUG
Group 2
chemotherapy and surgery
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 3
chemotherapy and surgery
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 4
Observation
Group Type
NO_INTERVENTION
No interventions assigned to this group
Group 5
chemotherapy
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 6
chemotherapy and surgery
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 7
chemotherapy and surgery
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 8
chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 9
chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Group 10
chemotherapy, surgery,
Group Type
EXPERIMENTAL
chemotherapy
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
chemotherapy
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* informed consent and follow-up warranted; group assignment completed within 6 weeks from diagnosis; no prior chemotherapy or radiotherapy
* Biopsy proven neuroblastoma
* Tumour genomic profile obtained in a NRL according to guidelines
* MYCN non-amplified
\*age ≤ 18 months
\* age ≤ 12 months
* informed consent and follow-up warranted; group assignment completed within 6 weeks from diagnosis; no prior chemotherapy or radiotherapy
* Tumour material available for biological studies according to guidelines
* Biopsy proven neuroblastoma confirmed in a National Reference Laboratory (NRL)
\* MYCN amplified
* Histology: differentiating, poorly differentiated, undifferentiated neuroblastoma or ganglioneuroblastoma nodular
* MYCN non-amplified
* age \>18 months
* Any histology
* MYCN non-amplified
* age ≤ 12 months
* Age less than or equal to 90 days when the suprarenal mass is discovered.
* Suprarenal mass detected by ultrasound and/or MRI. The suprarenal mass may be cystic and/or solid, but IT CANNOT REACH THE MIDLINE AND should MEASURE ≤ 5 CM AT THE LARGEST DIAMETER.
* No regional involvement: MRI scan does not show evidence of positive ipsi/contralateral lymph nodes or other spread outside the suprarenal gland.
* No metastatic involvement.
* Frozen plasma available.
* Informed consent.
* Availability to do the adequate follow-up
* Biopsy proven neuroblastoma
* Tumour genomic profile obtained in a NRL according to guidelines
* MYCN non-amplified
\*age ≤ 18 months
\* age ≤ 12 months
* informed consent and follow-up warranted; group assignment completed within 6 weeks from diagnosis; no prior chemotherapy or radiotherapy
* Tumour material available for biological studies according to guidelines
* Biopsy proven neuroblastoma confirmed in a National Reference Laboratory (NRL)
\* MYCN amplified
* Histology: differentiating, poorly differentiated, undifferentiated neuroblastoma or ganglioneuroblastoma nodular
* MYCN non-amplified
* age \>18 months
* Any histology
* MYCN non-amplified
* age ≤ 12 months
* Age less than or equal to 90 days when the suprarenal mass is discovered.
* Suprarenal mass detected by ultrasound and/or MRI. The suprarenal mass may be cystic and/or solid, but IT CANNOT REACH THE MIDLINE AND should MEASURE ≤ 5 CM AT THE LARGEST DIAMETER.
* No regional involvement: MRI scan does not show evidence of positive ipsi/contralateral lymph nodes or other spread outside the suprarenal gland.
* No metastatic involvement.
* Frozen plasma available.
* Informed consent.
* Availability to do the adequate follow-up
Exclusion Criteria
\* Diagnosis of ganglioneuroma or ganglioneuroblastoma intermixed INRG Stage L2
* any metastatic site
* MYCN amplification
* age \> 18 months INRG Stage Ms
* bone, pleura/lung and/or CNS metastasis
* MYCN amplification
* age \> 12 months
2. INTERMEDIATE RISK STUDY
\* Diagnosis of ganglioneuroma or ganglioneuroblastoma intermixed
INRG Stage L1 and INSS stage 1:
* MYCN non-amplified
* INSS stages 2, 3, 4, 4s
INRG Stage L2:
* neuroblastoma NOS
* MYCN amplification.
* age ≤ 18 months
INRG Stage M:
* MYCN amplification
* age \> 12 months
3. NEONATAL SUPRARENAL MASSES
* Age older than 90 days.
* Suprarenal mass bigger than 5 cm.
* Regional involvement.
* Metastatic involvement.
* Inability to undertake mandatory diagnostic studies (biological markers, US, MRI, MIBG).
* Follow-up not guaranteed by parents/guardians.
* any metastatic site
* MYCN amplification
* age \> 18 months INRG Stage Ms
* bone, pleura/lung and/or CNS metastasis
* MYCN amplification
* age \> 12 months
2. INTERMEDIATE RISK STUDY
\* Diagnosis of ganglioneuroma or ganglioneuroblastoma intermixed
INRG Stage L1 and INSS stage 1:
* MYCN non-amplified
* INSS stages 2, 3, 4, 4s
INRG Stage L2:
* neuroblastoma NOS
* MYCN amplification.
* age ≤ 18 months
INRG Stage M:
* MYCN amplification
* age \> 12 months
3. NEONATAL SUPRARENAL MASSES
* Age older than 90 days.
* Suprarenal mass bigger than 5 cm.
* Regional involvement.
* Metastatic involvement.
* Inability to undertake mandatory diagnostic studies (biological markers, US, MRI, MIBG).
* Follow-up not guaranteed by parents/guardians.
Minimum Eligible Age
90 Days
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto de Investigacion Sanitaria La Fe
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adela Cañete, MD, PhD
Role: STUDY_CHAIR
Hospital Universitari i Politècnic La Fe, Valencia, Spain
Gudrun Schleiermacher
Role: STUDY_CHAIR
Institut Curie
Kate Wheeler
Role: STUDY_CHAIR
Oxford: John Radcliffe Hospital, UK
Andrea di Cataldo
Role: STUDY_CHAIR
Policlinico Universitario, Italy
Vassilius Papadakis
Role: STUDY_CHAIR
Aghia Sophia Children's Hospital, Athens
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Monash Children's Hospital
Clayton, , Australia
Site Status
Perth Children's Hospital
Nedlands, , Australia
Site Status
Sydney Children's Hospital
Sydney, , Australia
Site Status
PHO Med Uni Graz
Graz, , Austria
Site Status
Department Kinder- und Jugendheilkunde
Innsbruck, , Austria
Site Status
Landes-Frauen- und Kinderklinik Linz
Linz, , Austria
Site Status
St. Anna Kinderspital
Vienna, , Austria
Site Status
Univ Klinik für Kinder- und Jugendheilkunde
Vienna, , Austria
Site Status
Hôpital Universitaire d'Anvers (UZA- Universitair Ziekenhuis Antwerpen)
Antwerp, , Belgium
Site Status
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
Brussels, , Belgium
Site Status
UCL Clíniques Universitaires Saint - Luc
Brussels, , Belgium
Site Status
Universitair Ziekenhuis Brussel
Brussels, , Belgium
Site Status
Universitair Ziekenhuis Gent
Ghent, , Belgium
Site Status
Universitair Ziekenhuis Leuven
Leuven, , Belgium
Site Status
CHC- Clinique de l'Espérance à Liège
Liège, , Belgium
Site Status
CHR de la Citadelle
Liège, , Belgium
Site Status
Aarhus University Hospital
Aarhus, , Denmark
Site Status
National State Hospital (Department of Pediatrics)
Copenhagen, , Denmark
Site Status
University Hospital of Odense (H.C. Andersen Children´s Hospital)
Odense, , Denmark
Site Status
Soroka Medical Center
Beersheba, , Israel
Site Status
Rambam Health Care Campus
Haifa, , Israel
Site Status
Schneider Children's Medical Center
Petah Tikva, , Israel
Site Status
Ichilov Hospital Sourasky Medical Center
Tel Aviv, , Israel
Site Status
Ospedale Pediatrico G. Salesi di Ancona (Centro Regionale Oncoematologia Pediatrica)
Ancona, , Italy
Site Status
Azienda Ospedaliera - Universitaria Ospedale Policlinico Consorziale
Bari, , Italy
Site Status
Azienda Ospedaliera Ospedali Riuniti di Bergamo
Bergamo, , Italy
Site Status
Azienda Ospedaliero- Universitaria di Bologna- Policlinico S. Orsola - Malpighi
Bologna, , Italy
Site Status
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, , Italy
Site Status
Ospedale Microcitemico
Cagliari, , Italy
Site Status
Oncology Policlinico- Department of Hematology
Catania, , Italy
Site Status
Azienda Ospedaliero-Universitaria di Ferrara- Oncoematologia Pediatrica
Ferrara, , Italy
Site Status
Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer
Florence, , Italy
Site Status
Oncology Gaslini Children's Hospital of Genova- Department of Hematology
Genova, , Italy
Site Status
Istituto Nazionale dei Tumori di Milano- Onco-ematologia Pediatrica
Milan, , Italy
Site Status
Azienda Ospedaliero-Universitaria Policlinico di Modena- Onco-ematologia Pediatrica
Modena, , Italy
Site Status
Azienda Ospedaliera Pediatrica Santobono Pausilipon
Napoli, , Italy
Site Status
Sec. Università degli studi di Napoli - Policlinico
Napoli, , Italy
Site Status
Azienda Ospedaliera-Universitaria di Padova- Clínica di Onco-ematologia Pediatrica
Padua, , Italy
Site Status
Ospedale dei Bambini G. Di Cristina
Palermo, , Italy
Site Status
Azienda Ospedaliero - Universitaria di Parma- Oncoematologia Pediatrica
Parma, , Italy
Site Status
Fondazione IRCCS - Policlinico San Matteo - Oncoematologia Pediadrica
Pavia, , Italy
Site Status
Azienda USL Di Pescara - U.O.C di Ematologia Clinica
Pescara, , Italy
Site Status
Ospedale Infermi di Rimini - U.O. Pediatria
Rimini, , Italy
Site Status
Ospedale Pediatrico Bambino Gesù- Oncoematologia pediatrica
Roma, , Italy
Site Status
Ospedale Policlinico Universitario Agostino Gemelli
Roma, , Italy
Site Status
Policlinico Umberto I
Roma, , Italy
Site Status
Casa Sollievo della Sofferenza
San Giovanni Rotondo, , Italy
Site Status
Azienda Ospedaliera Universitaria Senese - Clinica Pediatrica
Siena, , Italy
Site Status
Azienda Sanitaria Ospedaliera O.I.R.M.- Sant' Anna
Torino, , Italy
Site Status
Ospedale Cardinale G. Panico
Tricase, , Italy
Site Status
Ospedale Infantile Burlo Garofolo ( U.O. Emato-Oncologia Pediatrica - Università degli studi di Trieste)
Trieste, , Italy
Site Status
Policlinico G.B. Rossi- Oncoematologia Pediatrica
Verona, , Italy
Site Status
Haukeland University Hospital
Bergen, , Norway
Site Status
Oslo University Hospital, Rikshospitalet. (National coordinator)
Oslo, , Norway
Site Status
University Hospital of Northern Norway
Tromsø, , Norway
Site Status
St Olavs University Hospital
Trondheim, , Norway
Site Status
Hospital de Sabadell
Sabadell, Barcelona, Spain
Site Status
Hospital Universitario Montepríncipe
Boadilla del Monte, Madrid, Spain
Site Status
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Site Status
Hospital General Universitario de Albacete
Albacete, , Spain
Site Status
Hospital General Universitario de Alicante
Alicante, , Spain
Site Status
Complejo Hospitalario Torrecárdenas
Almería, , Spain
Site Status
Hospital Infanta Cristina
Badajoz, , Spain
Site Status
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
Hospital Materno Infantil Vall d'Hebron
Barcelona, , Spain
Site Status
Hospital Universitario Cruces
Bilbao, , Spain
Site Status
Hospital Universitario Reina Sofía
Córdoba, , Spain
Site Status
Hospital Universitario Materno Infantil Virgen de las Nieves
Granada, , Spain
Site Status
Hospital Materno Infantil de Jaén
Jaén, , Spain
Site Status
Hospital Universitario 12 de Octubre
Madrid, , Spain
Site Status
Hospital Universitario Infantil la Paz
Madrid, , Spain
Site Status
Hospital Universitario Infantil Niño Jesús
Madrid, , Spain
Site Status
Hospital Regional Universitario Carlos Haya - Hospital Materno Infantil
Málaga, , Spain
Site Status
Hospital Universitario Virgen de la Arrixaca
Murcia, , Spain
Site Status
Hospital Universitario Central de Asturias
Oviedo, , Spain
Site Status
Hospital Virgen del Camino
Pamplona, , Spain
Site Status
Hospital Universitario Donostia
San Sebastián, , Spain
Site Status
Hospital Universitario de Santiago
Santiago de Compostela, , Spain
Site Status
Hospital Universitario Virgen del Rocío
Seville, , Spain
Site Status
Hospital Universitario Virgen Macarena
Seville, , Spain
Site Status
Instituto de Investigacion Sanitaria La Fe
Valencia, , Spain
Site Status
Hospital Clínic Universitari
Valencia, , Spain
Site Status
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Site Status
Queen Silvia's Children's Hospital
Gothenburg, , Sweden
Site Status
Linköping University Hospital
Linköping, , Sweden
Site Status
Skåne University Hospital
Lund, , Sweden
Site Status
Karolinska University Hospital
Stockholm, , Sweden
Site Status
Norrlands University Hospital
Umeå, , Sweden
Site Status
Uppsala Academic Children's Hospital
Uppsala, , Sweden
Site Status
Kantonsspital Aarau
Aarau, , Switzerland
Site Status
Universitäts-Kinderspital beider Basel
Basel, , Switzerland
Site Status
Ospedale San Giovanni
Bellinzona, , Switzerland
Site Status
Inselspital Bern
Bern, , Switzerland
Site Status
HUG Hôpitaux Universitaires Genève
Geneva, , Switzerland
Site Status
CHUV - Centre Hospitalier Universitaire Vaudois - Unité d'hémato-oncologie pédiatrique
Lausanne, , Switzerland
Site Status
Luzerner Kantonsspital
Lucerne, , Switzerland
Site Status
Ostschweizer Kinderspital
Sankt Gallen, , Switzerland
Site Status
Universitäts-Kinderspital Zürich
Zurich, , Switzerland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Australia
Austria
Belgium
Denmark
Israel
Italy
Norway
Spain
Sweden
Switzerland
References
Explore related publications, articles, or registry entries linked to this study.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77. doi: 10.1200/JCO.1993.11.8.1466.
Reference Type
BACKGROUND
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1.
Reference Type
BACKGROUND
De Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009 Mar 1;27(7):1034-40. doi: 10.1200/JCO.2008.17.5877. Epub 2009 Jan 26.
Reference Type
BACKGROUND
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009 Mar 1;27(7):1026-33. doi: 10.1200/JCO.2008.16.0630. Epub 2009 Jan 26.
Reference Type
BACKGROUND
Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, Ribeiro A, Mosseri V, Rubie H, Munzer C, Thomas C, Valteau-Couanet D, Auvrignon A, Plantaz D, Delattre O, Couturier J; Societe Francaise des Cancers de l'Enfant (SFCE). Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer. 2007 Jul 16;97(2):238-46. doi: 10.1038/sj.bjc.6603820. Epub 2007 Jun 19.
Reference Type
BACKGROUND
Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Toma P, Rizzo A, Michon J, Holmes K. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005 Nov 20;23(33):8483-9. doi: 10.1200/JCO.2005.02.4661.
Reference Type
BACKGROUND
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009 Jan 10;27(2):298-303. doi: 10.1200/JCO.2008.16.6876. Epub 2008 Dec 1.
Reference Type
BACKGROUND
De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda AF, Pearson AD, De Kraker J, Ambros PF, de Rycke Y, Conte M, Bruzzi P, Michon J; SIOP Europe Neuroblastoma Group. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008 Oct 7;99(7):1027-33. doi: 10.1038/sj.bjc.6604640. Epub 2008 Sep 2.
Reference Type
BACKGROUND
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL; International Neuroblastoma Risk Group. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1.
Reference Type
BACKGROUND
Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, Ladenstein R, Brichard B, Bermudez JD, Couturier J, de Bernardi B, Pearson AJ, Michon J. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009 Mar 1;27(7):1014-9. doi: 10.1200/JCO.2007.14.5839. Epub 2009 Jan 26.
Reference Type
BACKGROUND
Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008 Mar 20;26(9):1504-10. doi: 10.1200/JCO.2007.12.3349.
Reference Type
BACKGROUND
Rubie H, Michon J, Plantaz D, Peyroulet MC, Coze C, Frappaz D, Chastagner P, Baranzelli MC, Mechinaud F, Boutard P, Lutz P, Perel Y, Leverger G, de Lumley L, Millot F, Stephan JL, Margueritte G, Hartmann O. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Br J Cancer. 1998 Jun;77(12):2310-7. doi: 10.1038/bjc.1998.384.
Reference Type
BACKGROUND
Castel V, Badal MD, Bezanilla JL, Llombart A, Ruiz-Jimenez JI, Sanchez de Toledo J, Melero C, Mulet J. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol. 1995 Jan;24(1):29-35. doi: 10.1002/mpo.2950240107.
Reference Type
BACKGROUND
Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L, Di Tullio MT, Bagnulo S, Mancini A, Carli M, Pession A, Arrighini A, Di Cataldo A, Tamaro P, Iasonni V, Taccone A, Rogers D, Boni L; Italian Cooperative Group dor Neuroblastoma. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1993 Sep;11(9):1770-9. doi: 10.1200/JCO.1993.11.9.1770.
Reference Type
BACKGROUND
Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, Casale F, Mazzocco K, Cecchetto G, Rizzo A, Bernardi B; Italian Cooperative Group for Neuroblastoma. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol. 2002 Jun;13(6):956-64. doi: 10.1093/annonc/mdf165.
Reference Type
BACKGROUND
Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, Wharam M, McWilliams N, Joshi V, Hayes FA. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991 May;9(5):789-95. doi: 10.1200/JCO.1991.9.5.789.
Reference Type
BACKGROUND
Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer. 2009 Jan;45(1):90-8. doi: 10.1016/j.ejca.2008.09.016. Epub 2008 Nov 6.
Reference Type
BACKGROUND
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784.
Reference Type
BACKGROUND
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14;341(16):1165-73. doi: 10.1056/NEJM199910143411601.
Reference Type
BACKGROUND
Brodeur GM, Maris JM, Yamashiro DJ, Hogarty MD, White PS. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):93-101. doi: 10.1097/00043426-199703000-00001.
Reference Type
BACKGROUND
Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999 Jul;17(7):2264-79. doi: 10.1200/JCO.1999.17.7.2264.
Reference Type
BACKGROUND
Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003 Mar;3(3):203-16. doi: 10.1038/nrc1014.
Reference Type
BACKGROUND
Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005 Feb;17(1):7-13. doi: 10.1097/01.mop.0000150631.60571.89.
Reference Type
BACKGROUND
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111-6. doi: 10.1056/NEJM198510313131802.
Reference Type
BACKGROUND
Ladenstein R, Ambros IM, Potschger U, Amann G, Urban C, Fink FM, Schmitt K, Jones R, Slociak M, Schilling F, Ritter J, Berthold F, Gadner H, Ambros PF. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol. 2001 Jan;36(1):83-92. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-9.
Reference Type
BACKGROUND
Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581-91. doi: 10.1200/JCO.1991.9.4.581.
Reference Type
BACKGROUND
Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):225-30. doi: 10.1056/NEJM199601253340404.
Reference Type
BACKGROUND
Luttikhuis ME, Powell JE, Rees SA, Genus T, Chughtai S, Ramani P, Mann JR, McConville CM. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer. 2001 Aug 17;85(4):531-7. doi: 10.1054/bjoc.2001.1960.
Reference Type
BACKGROUND
Schleiermacher G, Delattre O, Peter M, Mosseri V, Delonlay P, Vielh P, Thomas G, Zucker JM, Magdelenat H, Michon J. Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: a single-institution study. Int J Cancer. 1996 Apr 22;69(2):73-8. doi: 10.1002/(SICI)1097-0215(19960422)69:23.0.CO;2-S.
Reference Type
BACKGROUND
Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM; Children's Oncology Group. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005 Nov 24;353(21):2243-53. doi: 10.1056/NEJMoa052399.
Reference Type
BACKGROUND
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001 Jan;36(1):11-3. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-M.
Reference Type
BACKGROUND
Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS; United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetics Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol. 2001 Jun 15;19(12):3080-90. doi: 10.1200/JCO.2001.19.12.3080.
Reference Type
BACKGROUND
Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol. 1997 Jan;150(1):81-9.
Reference Type
BACKGROUND
Bown N, Lastowska M, Cotterill S, O'Neill S, Ellershaw C, Roberts P, Lewis I, Pearson AD; U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol. 2001 Jan;36(1):14-9. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-G.
Reference Type
BACKGROUND
Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Terpe HJ, Lampert F, Boecker W, Dockhorn-Dworniczak B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer. 1998 Jun;77(12):2223-9. doi: 10.1038/bjc.1998.370.
Reference Type
BACKGROUND
Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Benard J, Hartmann O, Nicholson JC, Ross FM, Brinkschmidt C, Laureys G, Caron H, Matthay KK, Feuerstein BG, Speleman F. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001 Mar 1;91(5):680-6. doi: 10.1002/1097-0215(200002)9999:99993.0.co;2-r.
Reference Type
BACKGROUND
Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005 Apr 1;23(10):2280-99. doi: 10.1200/JCO.2005.06.104.
Reference Type
BACKGROUND
Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinskchmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol. 2001 Jan;36(1):5-10. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-E.
Reference Type
BACKGROUND
Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuuring E, Brock P, Otten J, Gyselinck J, De Paepe A, Speleman F. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998 Oct;23(2):141-52. doi: 10.1002/(sici)1098-2264(199810)23:23.0.co;2-2.
Reference Type
BACKGROUND
Mosse YP, Diskin SJ, Wasserman N, Rinaldi K, Attiyeh EF, Cole K, Jagannathan J, Bhambhani K, Winter C, Maris JM. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007 Oct;46(10):936-49. doi: 10.1002/gcc.20477.
Reference Type
BACKGROUND
Janoueix-Lerosey I, Hupe P, Maciorowski Z, La Rosa P, Schleiermacher G, Pierron G, Liva S, Barillot E, Delattre O. Preferential occurrence of chromosome breakpoints within early replicating regions in neuroblastoma. Cell Cycle. 2005 Dec;4(12):1842-6. doi: 10.4161/cc.4.12.2257. Epub 2005 Dec 14.
Reference Type
BACKGROUND
Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A, Ribeiro A, Janoueix-Lerosey I, Delattre O. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene. 2005 May 5;24(20):3377-84. doi: 10.1038/sj.onc.1208486.
Reference Type
BACKGROUND
Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O'Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003 Jun 1;21(11):2077-84. doi: 10.1200/JCO.2003.03.025.
Reference Type
BACKGROUND
Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009 May 5;100(9):1471-82. doi: 10.1038/sj.bjc.6605014.
Reference Type
BACKGROUND
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988 Dec;6(12):1874-81. doi: 10.1200/JCO.1988.6.12.1874.
Reference Type
BACKGROUND
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999 Jul 15;86(2):364-72.
Reference Type
BACKGROUND
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999 Jul 15;86(2):349-63.
Reference Type
BACKGROUND
Kerbl R, Urban CE, Ambros IM, Dornbusch HJ, Schwinger W, Lackner H, Ladenstein R, Strenger V, Gadner H, Ambros PF. Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. J Clin Oncol. 2003 Nov 15;21(22):4228-34. doi: 10.1200/JCO.2003.10.168.
Reference Type
BACKGROUND
Kerbl R, Urban CE, Lackner H, Hofler G, Ambros IM, Ratschek M, Ambros PF. Connatal localized neuroblastoma. The case to delay treatment. Cancer. 1996 Apr 1;77(7):1395-401. doi: 10.1002/(SICI)1097-0142(19960401)77:73.0.CO;2-W.
Reference Type
BACKGROUND
Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003 Aug;4(8):472-80. doi: 10.1016/s1470-2045(03)01166-5.
Reference Type
BACKGROUND
Nadler EP, Barksdale EM. Adrenal masses in the newborn. Semin Pediatr Surg. 2000 Aug;9(3):156-64. doi: 10.1053/spsu.2000.7560.
Reference Type
BACKGROUND
Donoghue V, Ryan S, Twomey E. Perinatal tumours: the contribution of radiology to management. Pediatr Radiol. 2008 Jun;38 Suppl 3:S477-83. doi: 10.1007/s00247-008-0841-x. No abstract available.
Reference Type
BACKGROUND
Mahony R, McParland P. Approaches to the management of antenatally diagnosed congenital tumours. Pediatr Radiol. 2009 Nov;39(11):1173-8. doi: 10.1007/s00247-009-1163-3. Epub 2009 Mar 11.
Reference Type
BACKGROUND
Avni FE, Massez A, Cassart M. Tumours of the fetal body: a review. Pediatr Radiol. 2009 Nov;39(11):1147-57. doi: 10.1007/s00247-009-1160-6. Epub 2009 Feb 24.
Reference Type
BACKGROUND
Deeg KH, Bettendorf U, Hofmann V. Differential diagnosis of neonatal adrenal haemorrhage and congenital neuroblastoma by colour coded Doppler sonography and power Doppler sonography. Eur J Pediatr. 1998 Apr;157(4):294-7. doi: 10.1007/s004310050814.
Reference Type
BACKGROUND
Nuchtern JG. Perinatal neuroblastoma. Semin Pediatr Surg. 2006 Feb;15(1):10-6. doi: 10.1053/j.sempedsurg.2005.11.003.
Reference Type
BACKGROUND
Noguchi S, Masumoto K, Taguchi T, Takahashi Y, Tsuneyoshi M, Suita S. Adrenal cytomegaly: two cases detected by prenatal diagnosis. Asian J Surg. 2003 Oct;26(4):234-6. doi: 10.1016/s1015-9584(09)60312-2.
Reference Type
BACKGROUND
Barrette S, Bernstein ML, Leclerc JM, Champagne MA, Samson Y, Brossard J, Woods WG. Treatment complications in children diagnosed with neuroblastoma during a screening program. J Clin Oncol. 2006 Apr 1;24(10):1542-5. doi: 10.1200/JCO.2005.04.4602.
Reference Type
BACKGROUND
Suita S, Tajiri T, Higashi M, Tanaka S, Kinoshita Y, Takahashi Y, Tatsuta K. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan. Eur J Pediatr Surg. 2007 Feb;17(1):23-8. doi: 10.1055/s-2006-924640.
Reference Type
BACKGROUND
Chen CP, Chen SH, Chuang CY, Lee HC, Hwu YM, Chang PY, Chen ML, Chen BF. Clinical and perinatal sonographic features of congenital adrenal cystic neuroblastoma: a case report with review of the literature. Ultrasound Obstet Gynecol. 1997 Jul;10(1):68-73. doi: 10.1046/j.1469-0705.1997.10010068.x.
Reference Type
BACKGROUND
Daneman A, Baunin C, Lobo E, Pracros JP, Avni F, Toi A, Metreweli C, Ho SS, Moore L. Disappearing suprarenal masses in fetuses and infants. Pediatr Radiol. 1997 Aug;27(8):675-81. doi: 10.1007/s002470050210.
Reference Type
BACKGROUND
Granata C, Fagnani AM, Gambini C, Boglino C, Bagnulo S, Cecchetto G, Federici S, Inserra A, Michelazzi A, Riccipetitoni G, Rizzo A, Tamaro P, Jasonni V, De Bernardi B. Features and outcome of neuroblastoma detected before birth. J Pediatr Surg. 2000 Jan;35(1):88-91. doi: 10.1016/s0022-3468(00)80020-2.
Reference Type
BACKGROUND
Lee SY, Chuang JH, Huang CB, Hsiao CC, Wan YL, Ng SH, Lee TY, Ko SF. Congenital bilateral cystic neuroblastoma with liver metastases and massive intracystic haemorrhage. Br J Radiol. 1998 Nov;71(851):1205-7. doi: 10.1259/bjr.71.851.10434918.
Reference Type
BACKGROUND
Nishi M, Miyake H, Takeda T, Yonemori H, Hanai J, Kikuchi Y, Takasugi N. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma. Jpn J Clin Oncol. 1994 Oct;24(5):247-51.
Reference Type
BACKGROUND
Wang CH, Chen SJ, Yang LY, Tang RB. Neonatal adrenal hemorrhage presenting as a multiloculated cystic mass. J Chin Med Assoc. 2008 Sep;71(9):481-4. doi: 10.1016/S1726-4901(08)70153-9.
Reference Type
BACKGROUND
Masiakos PT, Gerstle JT, Cheang T, Viero S, Kim PC, Wales P. Is surgery necessary for incidentally discovered adrenal masses in children? J Pediatr Surg. 2004 May;39(5):754-8. doi: 10.1016/j.jpedsurg.2004.01.039.
Reference Type
BACKGROUND
Oue T, Inoue M, Yoneda A, Kubota A, Okuyama H, Kawahara H, Nishikawa M, Nakayama M, Kawa K. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005 Feb;40(2):359-63. doi: 10.1016/j.jpedsurg.2004.10.062.
Reference Type
BACKGROUND
Tsuchida Y, Ikeda H, Iehara T, Toyoda Y, Kawa K, Fukuzawa M. Neonatal neuroblastoma: incidence and clinical outcome. Med Pediatr Oncol. 2003 Jun;40(6):391-3. doi: 10.1002/mpo.10235. No abstract available.
Reference Type
BACKGROUND
Sauvat F, Sarnacki S, Brisse H, Medioni J, Rubie H, Aigrain Y, Gauthier F, Audry G, Helardot P, Landais P, Michon J, Hartmann O, Nihoul-Fekete C. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer. 2002 May 1;94(9):2474-80. doi: 10.1002/cncr.10502.
Reference Type
BACKGROUND
Crofton PM, Squires N, Davidson DF, Henderson P, Taheri S. Reliability of urine collection pads for routine and metabolic biochemistry in infants and young children. Eur J Pediatr. 2008 Nov;167(11):1313-9. doi: 10.1007/s00431-008-0733-y. Epub 2008 May 21.
Reference Type
BACKGROUND
Kellie SJ, Clague AE, McGeary HM, Smith PJ. The value of catecholamine metabolite determination on untimed urine collections in the diagnosis of neural crest tumours in children. Aust Paediatr J. 1986 Nov;22(4):313-5. doi: 10.1111/j.1440-1754.1986.tb02156.x.
Reference Type
BACKGROUND
Pussard E, Neveux M, Guigueno N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin Biochem. 2009 Apr;42(6):536-9. doi: 10.1016/j.clinbiochem.2008.10.022. Epub 2008 Nov 11.
Reference Type
BACKGROUND
Snow AB, Khalyfa A, Serpero LD, Capdevila OS, Kim J, Buazza MO, Gozal D. Catecholamine alterations in pediatric obstructive sleep apnea: effect of obesity. Pediatr Pulmonol. 2009 Jun;44(6):559-67. doi: 10.1002/ppul.21015.
Reference Type
BACKGROUND
Combaret V, Audoynaud C, Iacono I, Favrot MC, Schell M, Bergeron C, Puisieux A. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res. 2002 Jul 1;62(13):3646-8.
Reference Type
BACKGROUND
Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K, Ohira M, Nakagawara A, Kuroda H, Sugimoto T. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005 Aug 1;23(22):5205-10. doi: 10.1200/JCO.2005.02.014.
Reference Type
BACKGROUND
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
Reference Type
BACKGROUND
Ambros PF, Ambros IM, Kerbl R, Luegmayr A, Rumpler S, Ladenstein R, Amann G, Kovar H, Horcher E, De Bernardi B, Michon J, Gadner H. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med Pediatr Oncol. 2001 Jan;36(1):1-4. doi: 10.1002/1096-911X(20010101)36:13.0.CO;2-L.
Reference Type
BACKGROUND
Stark DD, Moss AA, Brasch RC, deLorimier AA, Albin AR, London DA, Gooding CA. Neuroblastoma: diagnostic imaging and staging. Radiology. 1983 Jul;148(1):101-5. doi: 10.1148/radiology.148.1.6856817.
Reference Type
BACKGROUND
Brody AS, Frush DP, Huda W, Brent RL; American Academy of Pediatrics Section on Radiology. Radiation risk to children from computed tomography. Pediatrics. 2007 Sep;120(3):677-82. doi: 10.1542/peds.2007-1910.
Reference Type
BACKGROUND
Semelka RC, Armao DM, Elias J Jr, Huda W. Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J Magn Reson Imaging. 2007 May;25(5):900-9. doi: 10.1002/jmri.20895.
Reference Type
BACKGROUND
Siegel MJ, Jaju A. MR imaging of neuroblastic masses. Magn Reson Imaging Clin N Am. 2008 Aug;16(3):499-513, vi. doi: 10.1016/j.mric.2008.04.007.
Reference Type
BACKGROUND
Sofka CM, Semelka RC, Kelekis NL, Worawattanakul S, Chung CJ, Gold S, Fordham LA. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging. 1999 Feb;17(2):193-8. doi: 10.1016/s0730-725x(98)00102-7.
Reference Type
BACKGROUND
Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002 Jul-Aug;22(4):911-34. doi: 10.1148/radiographics.22.4.g02jl15911.
Reference Type
BACKGROUND
Brisse HJ, Aubert B. [CT exposure from pediatric MDCT: results from the 2007-2008 SFIPP/ISRN survey]. J Radiol. 2009 Feb;90(2):207-15. doi: 10.1016/s0221-0363(09)72471-0. French.
Reference Type
BACKGROUND
Goske MJ, Applegate KE, Boylan J, Butler PF, Callahan MJ, Coley BD, Farley S, Frush DP, Hernanz-Schulman M, Jaramillo D, Johnson ND, Kaste SC, Morrison G, Strauss KJ, Tuggle N. The Image Gently campaign: working together to change practice. AJR Am J Roentgenol. 2008 Feb;190(2):273-4. doi: 10.2214/AJR.07.3526. No abstract available.
Reference Type
BACKGROUND
Boglino C, Martins AG, Ciprandi G, Sousinha M, Inserra A. Spinal cord vascular injuries following surgery of advanced thoracic neuroblastoma: an unusual catastrophic complication. Med Pediatr Oncol. 1999 May;32(5):349-52. doi: 10.1002/(sici)1096-911x(199905)32:53.0.co;2-p.
Reference Type
BACKGROUND
Ou P, Schmit P, Layouss W, Sidi D, Bonnet D, Brunelle F. CT angiography of the artery of Adamkiewicz with 64-section technology: first experience in children. AJNR Am J Neuroradiol. 2007 Feb;28(2):216-9.
Reference Type
BACKGROUND
Goo HW, Choi SH, Ghim T, Moon HN, Seo JJ. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol. 2005 Aug;35(8):766-73. doi: 10.1007/s00247-005-1459-x. Epub 2005 Apr 28.
Reference Type
BACKGROUND
Uhl M, Altehoefer C, Kontny U, Il'yasov K, Buchert M, Langer M. MRI-diffusion imaging of neuroblastomas: first results and correlation to histology. Eur Radiol. 2002 Sep;12(9):2335-8. doi: 10.1007/s00330-002-1310-9. Epub 2002 Mar 19.
Reference Type
BACKGROUND
Mendichovszky IA, Marks SD, Simcock CM, Olsen OE. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol. 2008 May;38(5):489-96; quiz 602-3. doi: 10.1007/s00247-007-0633-8. Epub 2007 Oct 18.
Reference Type
BACKGROUND
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
Reference Type
BACKGROUND
Lumbroso J, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Lemerle J, Parmentier C. [Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases]. Bull Cancer. 1988;75(1):97-106. French.
Reference Type
BACKGROUND
Khafagi FA, Shapiro B, Fischer M, Sisson JC, Hutchinson R, Beierwaltes WH. Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med. 1991;18(3):191-8. doi: 10.1007/BF02262730.
Reference Type
BACKGROUND
Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, Hartmann O, Hoefnagel CA, Jamadar DA, Kloos R, Lizotte P, Lumbroso J, Rufini V, Shulkin BL, Sisson JC, Thein A, Troncone L. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med. 1997 Sep;38(9):1352-7.
Reference Type
BACKGROUND
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med. 1985 Jun;26(6):576-85.
Reference Type
BACKGROUND
Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998 Apr;39(4):679-88.
Reference Type
BACKGROUND
Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med. 1999 Sep;43(3):217-23.
Reference Type
BACKGROUND
Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980 Apr;21(4):349-53.
Reference Type
BACKGROUND
Khafagi FA, Shapiro B, Gross MD. The adrenal gland. In: Maisey MN, Britton KE, Gilday DL, eds. Clinical Nuclear Medicine. 2nd ed: London Chapman & Hall 1989:271-91.
Reference Type
BACKGROUND
Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J. 1974 Aug 3;3(5926):301-7. doi: 10.1136/bmj.3.5926.301.
Reference Type
BACKGROUND
Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer. 1986 Jul 15;58(2 Suppl):598-602. doi: 10.1002/1097-0142(19860715)58:2+3.0.co;2-c.
Reference Type
BACKGROUND
Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med. 1993 Jul;23(3):231-42. doi: 10.1016/s0001-2998(05)80104-7.
Reference Type
BACKGROUND
Jacobs A, Delree M, Desprechins B, Otten J, Ferster A, Jonckheer MH, Mertens J, Ham HR, Piepsz A. Consolidating the role of *I-MIBG-scintigraphy in childhood neuroblastoma: five years of clinical experience. Pediatr Radiol. 1990;20(3):157-9. doi: 10.1007/BF02012960.
Reference Type
BACKGROUND
Lumbroso JD, Guermazi F, Hartmann O, Coornaert S, Rabarison Y, Leclere JG, Couanet D, Bayle C, Caillaud JM, Lemerle J, et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res. 1988;271:689-705. No abstract available.
Reference Type
BACKGROUND
Parisi MT, Greene MK, Dykes TM, Moraldo TV, Sandler ED, Hattner RS. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992 Oct;27(10):768-73. doi: 10.1097/00004424-199210000-00003.
Reference Type
BACKGROUND
Perel Y, Conway J, Kletzel M, Goldman J, Weiss S, Feyler A, Cohn SL. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):13-8. doi: 10.1097/00043426-199901000-00004.
Reference Type
BACKGROUND
Moyes J, McCready VR, Fullbrook AC. Neuroblastoma MIBG in its diagnosis and management: Springer-Verlag Berlin and Heidelberg GmbH & Co. K 1989.
Reference Type
BACKGROUND
Hoefnagel CA, De Kraker J, Valdes Olmos RA, Voute PA. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med. 1995 Dec;39(4 Suppl 1):61-4.
Reference Type
BACKGROUND
Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med (1991). 1991 Oct-Dec;35(4):220-3.
Reference Type
BACKGROUND
Mairs RJ. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents. Eur J Cancer. 1999 Aug;35(8):1171-3. doi: 10.1016/s0959-8049(99)00114-8. No abstract available.
Reference Type
BACKGROUND
Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans. J Nucl Med. 1990 Feb;31(2):129-34.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.siope.eu/activities/eu-projects/encca/
The European Network for Cancer Research in Children and Adolescents (ENCCA) is a Network of Excellence Funded by the European Union's 7th Framework Programme (FP7): See WP10
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LINES
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
NCT00404495
COMPLETED
PHASE2
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
NCT02641314
COMPLETED
PHASE2
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
NCT00025597
COMPLETED
PHASE2
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
NCT01962103
COMPLETED
PHASE1/PHASE2
Therapy for Children With Neuroblastoma
NCT00135135
COMPLETED
PHASE2
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
NCT00311584
COMPLETED
PHASE2
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
NCT02104986
COMPLETED
PHASE2
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
NCT06480526
RECRUITING
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
NCT00295919
COMPLETED
PHASE1
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
NCT01467986
COMPLETED
PHASE2
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
NCT02245997
COMPLETED
EARLY_PHASE1
Racotumomab in Patients With High-risk Neuroblastoma
NCT02998983
COMPLETED
PHASE2
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
NCT01418495
COMPLETED
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
NCT06528496
RECRUITING
PHASE2
Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
NCT00901849
COMPLETED
PHASE1
Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma
NCT00053950
TERMINATED
PHASE1
High-Risk Neuroblastoma Chemotherapy Without G-CSF
NCT02786719
COMPLETED
NA
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
NCT01802814
COMPLETED
PHASE3
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
NCT01505608
TERMINATED
PHASE1/PHASE2
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
NCT00918320
COMPLETED
PHASE2
Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL
NCT05811910
UNKNOWN
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma
NCT00025610
COMPLETED
PHASE2
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
COMPLETED
PHASE2
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
NCT02025881
TERMINATED
PHASE1/PHASE2
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171
RECRUITING
PHASE2